Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > Arrowhead Subsidiary, Insert Therapeutics, Awarded Patent for Cyclosert™ Camptothecin, the Company’s Lead Oncology Candidate

Abstract:
Insert Therapeutics, Inc., a majority-owned subsidiary of Arrowhead Research Corporation (NASDAQ:ARWR), announced today the issuance of a patent covering its lead oncology product, IT-101. IT 101 is a conjugate of Insert's proprietary drug delivery molecule, Cyclosert™, and the potent anti-cancer compound camptothecin. The newly-issued United States Patent No. 7,270,808 entitled "Cyclodextrin-based polymers for therapeutic delivery" covers Cyclosert-linked prodrugs, including camptothecin and camptothecin derivatives.

Arrowhead Subsidiary, Insert Therapeutics, Awarded Patent for Cyclosert™ Camptothecin, the Company’s Lead Oncology Candidate

PASADENA, CA | Posted on September 24th, 2007

IT-101 is a nanoparticle therapeutic and has been in Phase I clinical trials since July 2006. In June 2007, interim Phase I data was published in the 2007 American Society for Clinical Oncology (ASCO) Proceedings (Abstract ID 32638), and reported stable disease in several patients who completed the six-cycle treatment regimen.

"The granting of this patent, that covers conjugates of the Cyclosert™ delivery polymers with camptothecin as well as a large number of other therapeutics, is an important milestone in our path to becoming a multi-product therapeutics company," said John Petrovich, President and Chief Executive Officer of Insert. "It enables us to continue our plan to build a portfolio of novel nanoparticle therapeutics that will benefit patients with cancer and a wide range of other diseases and conditions."

The full text of the Cyclosert-camptothecin patent may be found by conducting a patent number search utilizing the U.S. Patent Office's web site at http://www.uspto.gov/patft/ .

####

About Arrowhead Research Corporation
Arrowhead Research Corporation (NASDAQ:ARWR) is a publicly-traded nanotechnology company commercializing new technologies in the areas of life sciences, electronics, and energy. Arrowhead is building value for shareholders through the progress of majority owned subsidiaries founded on nanotechnologies originally developed at universities. The company works closely with universities to source early stage deals and to generate rights to intellectual property covering promising new nanotechnologies. Currently, Arrowhead has five subsidiaries commercializing nanotech products and applications, including anti-cancer drugs, RNAi therapeutics, fullerene-based anti-oxidants, carbon-based electronics and compound semiconductor materials. For more information about Arrowhead and its subsidiary companies, please visit our website at http://www.arrowheadresearch.com .

About Insert Therapeutics

Insert Therapeutics, Inc. ( http://www.insertt.com ), a majority-owned subsidiary of Arrowhead Research Corporation (NASDAQ:ARWR), is using its proprietary, nano-engineered, polymeric delivery system, CyclosertTM, to design, develop and commercialize drug-delivery-enhanced small-molecule therapeutics and nucleic acids. Cyclosert uses cyclodextrins as building blocks to create an entirely new class of biocompatible materials - linear cyclodextrin-containing polymers that are non-toxic and non-immunogenic at therapeutic doses. Insert’s affiliate company, Calando Pharmaceuticals, is using a related system for the systemic delivery of siRNA. The companies are pursuing this goal through internal research and development, and also through collaborations and partnerships with pharmaceutical and biotechnology companies.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the future success of our clinical studies, our ability to successfully develop and manufacture products, rapid technological change in our industry, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, and other SEC filings discuss these and other important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.

For more information, please click here

Contacts:
Arrowhead Research
Virginia Dadey
212-541-3707

or
Insert Therapeutics
John G. Petrovich
626-683-7200

Copyright © Business Wire 2007

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Nanomedicine

These microscopic fish are 3-D-printed to do more than swim: Researchers demonstrate a novel method to build microscopic robots with complex shapes and functionalities August 26th, 2015

Glitter from silver lights up Alzheimer's dark secrets August 25th, 2015

Cervical cancer detection goes portable August 25th, 2015

Louisiana Tech University researchers discover synthesis of a new nanomaterial: Interdisciplinary team creates biocomposite for first time using physiological conditions August 24th, 2015

Announcements

Successful boron-doping of graphene nanoribbon August 27th, 2015

Nanolab Technologies LEAPS Forward with High-Performance Analysis Services to the World: Nanolab Orders Advanced Local Electrode Atom Probe (LEAP®) Microscope from CAMECA Unit of AMETEK Materials Analysis Division August 27th, 2015

National Space Society Welcomes Janet Ivey As New NSS Governor: Janet Ivey of Janet's Planet is NOW IN ORBIT as a member of the Board of Governors of the National Space Society August 27th, 2015

Researchers combine disciplines, computational programs to determine atomic structure August 26th, 2015

Patents/IP/Tech Transfer/Licensing

Developing Component Scale Composites Using Nanocarbons August 26th, 2015

Industrial Nanotech, Inc. Provides Update On Hospital Project, PCAOB Audit, and New Heat Shield™ Line August 24th, 2015

Revolutionary MIT-Developed Nanotechnology Company Showcases at CAMX in Dallas August 20th, 2015

'Quantum dot' technology may help light the future August 19th, 2015

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







Car Brands
Buy website traffic